Abstract:Objective:We conducted a real-world multi-center clinical study with a large sample size to comprehensively evaluate the performance of three commercial hepatitis C virus (HCV) core antigen assays. The study aimed to evaluate the performance for their use in HCV infection screening, and to provide clues for further improving the sensitivity and specificity of the assays.Methods:Key performance indicators including the lower limit of detection (LOD), diagnostic sensitivity, and specificity of three HCV antigen assays (the Architect, Laibo, and ChemClin HCV core antigen assays) were evaluated using commercial seroconversion panels reflecting early HCV infection and clinical routine serum samples of outpatients and inpatients from 3 tertiary hospitals from January 2018 to April 2022. Factors that affect the performance indicators were further investigated.Results:The window period for detecting HCV infection with the three antigen assays was equal to or slightly longer than that of the RNA assay, but all are shorter than that of the anti-HCV assay. There was a good linear positive correlation between HCV core antigen and HCV RNA levels in treatment naive patients with hepatitis C ( r=0.90, P<0.01). For the most common genotype 1b strain in China, the LOD of the three HCV assays were equivalent to 531 IU/ml (Architect), 3,698 IU/mL (Laibo), and 4,624 IU/mL (ChemClin) HCV RNA, respectively. Due to the skewed distribution of HCV RNA levels in treatment-naive hepatitis C patients, more than 95% of the patients had viral loads higher than 6 166 IU/ml. Therefore, the three HCV antigens assays still maintained a satisfactory diagnostic sensitivity (94.33%-99.40%). Among 54 immunodeficient patients (leukemia patients) with HCV infection, 9% (5/54) had negative anti-HCV results, while the HCV antigen assays found all these infectors. Through further experiments, we revealed the amino acid polymorphism in the core region of genotype 3 strain impaired the sensitivity of all three HCV antigen assays. In addition, the sensitivity of the two domestic assays was impaired by anti-HCV antibodies in the serum. The specificity of HCV antigen assays for diagnosing hepatitis C is 99.94% to 99.98%. The rheumatoid factors, autoantibodies, and other unknown interference substances can lead to a small number of low level, "false positive" antigen results. Conclusions:HCV core antigen assay may be used as a satisfactory approach of infection screening, especially for the immunodeficient patents. However, the sensitivity and specificity of the assays are influenced by multiple factors, which should be further improved.

Clinical Evaluation of Detecting Anti-hepatitis C Virus Antibodies by Enzymelinked Immunosobent Assay Based on Different Region Antigens of Hepatitis C Virus

Novel double-antigen sandwich immunoassay for human hepatitis B core antibody.

Clinical application of enzyme immunoassay for the detection of hepatitis C virus core antigen

[Development of a Diagnostic Kit of Enzyme-Linked Immunoassay for Detecting Serum Anti-Hepatitis E Virus IgG].

Establishment and methodological evaluation of a chemiluminescence assay for detection of anti‐envelope protein (E1, E2) antibodies in the serum of hepatitis C virus‐infected patients

Research and Application of the Diagnostic Kit for Anti-Hepatitis E Virus IgG Detection

Evaluation of two anti-hepatitis e virus lgM kits

Study on the Different HCV Antibody Detection by Dot Immunoassay

Reactivity of Antigens Encoded by Different Gene Fragments of HCV

Evaluation on Performance Index of Different Domestic and Imported Anti-Hcv EIA Kits

Performance characteristics of the EIAgen hepatitis C virus antibody kit assay

The ELISA method with synthetic peptides to detect the serotypes of hepatitis C virus

Evaluation of Two Anti-Hepatitis E Virus IgM Kits

Clinical Application of Detection for Total Core Antigen of Hepatitis C Virus

Study on the Significance of S/Co Ratio of a Domestic Reagent Used for Anti-Hepatitis C Virus Antibody Detection

Novel Evolved Immunoglobulin (Ig)-Binding Molecules Enhance the Detection of IgM Against Hepatitis C Virus

A New Colorimetric Assay Method for the Detection of Anti-Hepatitis C Virus Antibody with High Sensitivity.

Detection of Hepatitis C Virus RNA by Coated Microtiter Plate Hybridization

A multi-center performance evaluation of different hepatitis C virus core antigen assays for clinical infection screening

RELATIONSHIP BETWEEN LOAD OF HCV RNA AND ANTIBODIES AGAINST REGIONAL SPECIFIC PROTEINS OF HCV IN SERUM

Development of a competitive ELISA for detecting antibodies against genotype 1 hepatitis E virus